Arbutus Biopharma Statistics, Revenue Totals, Facts & News (2022)
Last Updated on: February 25th, 2022
Here are a few of the most interesting Arbutus Biopharma statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
What is Arbutus Biopharma?
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination regimen that will transform the HBV treatment landscape and cure hepatitis B virus disease. (source)
Arbutus Biopharma Employee Count
Number of Arbutus Biopharma employees:
Last updated 1/1/20
Please note that some of these numbers are easier to find than others. A few of these Arbutus Biopharma statistics come from their own reports, but some are based on news reports and not official company tallies. No information contained on DMR should be relied upon to make investment decisions. Basically, this is the best I can find and I don’t guarantee anything to be 100%.